Clinical Trial Update: Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM005 in Patients [Phase 1, Phase 2]

View source ↗

Summary

This report summarizes pharmacokinetics, biodistribution, radiation dose, and safety findings from a Phase 1/2 study of the radiopharmaceutical 68Ga-NYM005 in p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• 68Ga-NYM005 (NYM005)

Snippet

Sponsor: Norroy Bioscience Co., LTD | Conditions: Clear Cell Renal Cell Carcinoma Metastatic | Phase 1, Phase 2 | Status: COMPLETED